Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

SEC Charges Biotech R&D Head With Lying

by Michael McCoy
June 7, 2010 | A version of this story appeared in Volume 88, Issue 23

The Securities & Exchange Commission has charged Elizabeth A. Dragon, the former senior vice president of R&D at biotech firm Sequenom, with making false statements to investors about her company’s prenatal test for Down syndrome. According to SEC, Dragon claimed that the test’s highly accurate results were obtained on a “blinded” basis. In fact, the agency alleges, Dragon “provided her scientists with the known outcomes of the samples, which allowed them to manipulate the data in order to produce more accurate results.” Dragon and Sequenom’s CEO were fired last year (C&EN, Oct. 5, 2009, page 23).

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.